HC Bioscience, Inc.

A New Era of Protein Engineering with tRNA Therapeutics.

Add To Watchlist
General Information
Company Name
HC Bioscience, Inc.
Founded Year
2021
Location (Offices)
Cambridge, United States +2
Founders / Decision Makers
Leslie Williams - Co-Founder, President & CEO José Lora - Chief Scientific Officer
Number of Employees
38
Industries
Biotechnology, Health Care, Life Sciences
Funding Stage
Series A
Social Media

HC Bioscience, Inc. - Company Profile

hC Bioscience, Inc. is pioneering a new era of protein engineering with tRNA therapeutics, aiming to elevate the standard of care for patients. Founded in 2021 and headquartered in the United States, hC Bioscience is dedicated to developing first-in-class tRNA-based therapeutics to target protein dysfunction associated with genetically defined diseases. Their revolutionary precision protein editing therapies have the potential to treat a myriad of diseases, irrespective of the gene or mutation location. The company recently secured a noteworthy $16.00M Series A investment on November 4, 2022, attracting support from prominent investors including 8VC, Arch Venture Partners, Panacea Venture, Taiho Ventures, and Takeda Ventures. With its innovative approach and robust investor backing, hC Bioscience is poised to make significant strides in the biotechnology and health care industries.

Taxonomy: Protein engineering, Therapeutics, tRNA-based, Precision medicine, Protein editing, Genetic diseases, Innovation, Pioneering, Genome editing, Proteome modification

Funding Rounds & Investors of HC Bioscience, Inc. (2)

View All
Funding Stage Amount No. Investors Investors Date
Series A $16.00M 5
8VC, investor in HC Bioscience, Inc.'s Series A round Arch Venture Partners, investor in HC Bioscience, Inc.'s Series A round Panacea Venture, investor in HC Bioscience, Inc.'s Series A round Taiho Ventures, investor in HC Bioscience, Inc.'s Series A round Takeda Pharma, investor in HC Bioscience, Inc.'s Series A round
04 Nov 2022
Series A $24.00M 3
8VC, investor in HC Bioscience, Inc.'s Series A round Arch Venture Partners, investor in HC Bioscience, Inc.'s Series A round Takeda Pharma, investor in HC Bioscience, Inc.'s Series A round
23 Feb 2022

Latest News of HC Bioscience, Inc.

View All

No recent news or press coverage available for HC Bioscience, Inc..

Similar Companies to HC Bioscience, Inc.

View All
Alltrna - Similar company to HC Bioscience, Inc.
Alltrna The world’s first transfer RNA (tRNA) platform company. We are unlocking the vast therapeutic potential within #tRNA.
aTyr Pharma - Similar company to HC Bioscience, Inc.
aTyr Pharma aTyr is a biotherapeutics company engaged in the development of innovative medicines based on novel biology.
Cimeio Therapeutics - Similar company to HC Bioscience, Inc.
Cimeio Therapeutics Reinventing cell therapy through our leadership in the emerging field of epitope shielding
GRO Biosciences - Similar company to HC Bioscience, Inc.
GRO Biosciences GRObio’s groundbreaking science expands the amino acid alphabet to deliver on the promise of protein-based therapies.
Alyra Therapeutics, Inc. - Similar company to HC Bioscience, Inc.
Alyra Therapeutics, Inc. Next-generation precision oncology
Circle Decoration Circle Decoration

Want to dive deeper into HC Bioscience, Inc.? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now